Lactiplantibacillus plantarum GUANKE ameliorates influenza a virus-induced inflammation and lung barrier dysfunction through enhancing mitophagy and improving oxidative phosphorylation.
- 2026-02-10
- Cellular and molecular life sciences : CMLS 83(1)
- PubMed: 41667656
- DOI: 10.1007/s00018-026-06081-9
Study Design
- Population
- C57BL/6 murine models
- Methods
- GUANKE (5×10^9 CFU/day) or exogenous linoleic acid (40 mg/kg) supplementation against influenza A virus (IAV)-induced pulmonary damage
Pulmonary inflammatory response represents a predominant complication arising from influenza virus infections. This investigation elucidates the protective efficacy of Lactiplantibacillus plantarum GUANKE (GUANKE) supplementation against influenza A virus (IAV)-induced pulmonary damage in C57BL/6 murine models, with particular emphasis on its mechanistic underpinnings. The results showed that the use of GUANKE (5 × 109 CFU/day) or exogenous linoleic acid (a metabolite of GUANKE) supplementation (40 mg/kg) significantly attenuated inflammatory cytokine secretion while counteracting virus-mediated downregulation of pulmonary barrier proteins. Mechanistic profiling revealed that GUANKE and GUANKE-derived linoleic acid modulates mitochondrial quality control through enhanced Parkin-dependent mitophagy coupled with restored mitochondrial oxidative phosphorylation (OXPHOS) capacity, thereby providing protection in IAV-infected mice.
Research Insights
| Supplement | Dose | Health Outcome | Effect Type | Effect Size | Source |
|---|---|---|---|---|---|
| Lactococcus lactis R1058 | — | Improved Lung Barrier Function | Beneficial | Moderate | View sourcecounteracting virus-mediated downregulation of pulmonary barrier proteins |
| Lactococcus lactis R1058 | — | Reduced Lung Inflammation | Beneficial | Moderate | View sourceGUANKE supplementation against influenza A virus (IAV)-induced pulmonary damage... significantly attenuated inflammatory cytokine secretion |